(Q38603309)

4 September 2017

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders (English)

1 reference

4 September 2017

0 references

1 reference

Michael G Schlossmacher

Michael G Schlossmacher

11

0 references

Marcel Verbeek

Marcel M Verbeek

10

0 references

Dag Aarsland

Dag Aarsland

7

0 references

Brit Mollenhauer

1

Brit Mollenhauer

1 reference

4 September 2017

2

Lucilla Parnetti

1 reference

Walter J Schulz-Schaeffer

4 September 2017

6

Walter J Schulz-Schaeffer

1 reference

4 September 2017

Irena Rektorova

3

1 reference

4 September 2017

Milica G Kramberger

4

1 reference

4 September 2017

Maria Pikkarainen

5

1 reference

4 September 2017

Per Svenningsson

8

1 reference

4 September 2017

Lucia Farotti

9

1 reference

4 September 2017

language of work or name

English

0 references

publication date

10 October 2015

1 reference

Journal of Neurochemistry

4 September 2017

28

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

4 September 2017

139 Suppl 1

1 reference

4 September 2017

290-317

1 reference

The epidemiology of dementia associated with Parkinson's disease

4 September 2017

1 reference

Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease

21 January 2018

1 reference

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

21 January 2018

1 reference

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

21 January 2018

1 reference

Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study

21 January 2018

1 reference

Spared caudal brainstem SERT binding in early Parkinson's disease

21 January 2018

1 reference

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

21 January 2018

1 reference

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

21 January 2018

1 reference

CSF Aβ42 predicts early-onset dementia in Parkinson disease

21 January 2018

1 reference

The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.

21 January 2018

1 reference

Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease.

21 January 2018

1 reference

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

21 January 2018

1 reference

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

21 January 2018

1 reference

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

21 January 2018

1 reference

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease

21 January 2018

1 reference

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

21 January 2018

1 reference

Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

21 January 2018

1 reference

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening

21 January 2018

1 reference

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

21 January 2018

1 reference

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

Frequency of stages of Alzheimer-related lesions in different age categories

21 January 2018

1 reference

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies

21 January 2018

1 reference

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update

21 January 2018

1 reference

The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma

21 January 2018

1 reference

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation

21 January 2018

1 reference

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

21 January 2018

1 reference

Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.

21 January 2018

1 reference

Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study

21 January 2018

1 reference

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.

21 January 2018

1 reference

Exosomal cell-to-cell transmission of alpha synuclein oligomers.

21 January 2018

1 reference

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

21 January 2018

1 reference

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology.

21 January 2018

1 reference

Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival

21 January 2018

1 reference

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

21 January 2018

1 reference

The effects of cerebral ischemia on the rat choroid plexus

21 January 2018

1 reference

The neurotransmitter serotonin interrupts α-synuclein amyloid maturation

21 January 2018

1 reference

Genetics of Parkinson disease: paradigm shifts and future prospects.

21 January 2018

1 reference

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.

21 January 2018

1 reference

Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?

21 January 2018

1 reference

Multiple-system atrophy: a new alpha-synuclein disease?

21 January 2018

1 reference

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

21 January 2018

1 reference

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

21 January 2018

1 reference

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

21 January 2018

1 reference

CSF biomarkers and clinical progression of Parkinson disease

21 January 2018

1 reference

The progression of pathology in Parkinson's disease

21 January 2018

1 reference

Neuropathology underlying clinical variability in patients with synucleinopathies

21 January 2018

1 reference

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

21 January 2018

1 reference

The spread of neurodegenerative disease.

21 January 2018

1 reference

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

21 January 2018

1 reference

Neuropathologic substrates of Parkinson disease dementia

21 January 2018

1 reference

Dementia from Alzheimer disease and mixed pathologies in the oldest old.

21 January 2018

1 reference

Neuropathological spectrum of synucleinopathies

21 January 2018

1 reference

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia

21 January 2018

1 reference

CSF biomarkers in different phenotypes of Parkinson disease

21 January 2018

1 reference

Prevalence of dementia disorders in the oldest-old: an autopsy study.

21 January 2018

1 reference

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases

21 January 2018

1 reference

The Glymphatic System: A Beginner's Guide

21 January 2018

1 reference

The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease

21 January 2018

1 reference

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

21 January 2018

1 reference

Positron emission tomography of striatal serotonin transporters in Parkinson disease

21 January 2018

1 reference

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

21 January 2018

1 reference

Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

21 January 2018

1 reference

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

21 January 2018

1 reference

Clearance and deposition of extracellular alpha-synuclein aggregates in microglia.

21 January 2018

1 reference

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

21 January 2018

1 reference

Structural and functional features of central nervous system lymphatic vessels

21 January 2018

1 reference

CSF biomarkers: pinpointing Alzheimer pathogenesis

21 January 2018

1 reference

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

21 January 2018

1 reference

Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias.

21 January 2018

1 reference

Movement disorders in cerebrovascular disease

21 January 2018

1 reference

Dopamine receptor immunohistochemistry in the rat choroid plexus.

21 January 2018

1 reference

Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease

21 January 2018

1 reference

Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort

21 January 2018

1 reference

Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

21 January 2018

1 reference

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

21 January 2018

1 reference

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

21 January 2018

1 reference

α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system

21 January 2018

1 reference

Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.

21 January 2018

1 reference

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

21 January 2018

1 reference

Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes.

21 January 2018

1 reference

CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.

21 January 2018

1 reference

Low sensitivity in clinical diagnoses of dementia with Lewy bodies

21 January 2018

1 reference

Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

21 January 2018

1 reference

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

21 January 2018

1 reference

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation

21 January 2018

1 reference

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

Cerebrospinal fluid biomarkers in Parkinson disease

21 January 2018

1 reference

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

21 January 2018

1 reference

Serotonergic dysfunction in Parkinson's disease and its relevance to disability.

21 January 2018

1 reference

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study

21 January 2018

1 reference

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

21 January 2018

1 reference

CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease

21 January 2018

1 reference

Biomarkers in Alzheimer's disease.

21 January 2018

1 reference

Subcortical ischaemic vascular dementia

21 January 2018

1 reference

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology

21 January 2018

1 reference

Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.

21 January 2018

1 reference

The neuropathology of probable Alzheimer disease and mild cognitive impairment

21 January 2018

1 reference

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

21 January 2018

1 reference

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

21 January 2018

1 reference

Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus.

21 January 2018

1 reference

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid

21 January 2018

1 reference

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

Genome-wide association study reveals genetic risk underlying Parkinson's disease

21 January 2018

1 reference

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.

21 January 2018

1 reference

CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.

21 January 2018

1 reference

Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.

21 January 2018

1 reference

CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans.

21 January 2018

1 reference

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

21 January 2018

1 reference

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort

21 January 2018

1 reference

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

Bundles of amyloid precursor protein-immunoreactive axons in human cerebrovascular white matter lesions.

21 January 2018

1 reference

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

21 January 2018

1 reference

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

21 January 2018

1 reference

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

21 January 2018

1 reference

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

21 January 2018

1 reference

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease

21 January 2018

1 reference

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

21 January 2018

1 reference

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy

21 January 2018

1 reference

Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.

21 January 2018

1 reference

Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.

21 January 2018

1 reference

Phosphorylated α-synuclein in Parkinson's disease

21 January 2018

1 reference

Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy

21 January 2018

1 reference

Sleep drives metabolite clearance from the adult brain

21 January 2018

1 reference

Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion.

21 January 2018

1 reference

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

21 January 2018

1 reference

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

21 January 2018

1 reference

Alterations of the blood–brain barrier in cerebral white matter lesions in the ageing brain

21 January 2018

1 reference

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

21 January 2018

1 reference

Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JNC.13390

1 reference

4 September 2017

1 reference